Business and Finance

In this latest Harvard Business School Healthcare Alumni Association Q&A, Susan Wilner Golden, DSc, lecturer at the Stanford Graduate School of Business, reveals an untapped $22 trillion global opportunity for all companies and others supporting healthy aging and longer life spans.

Decision is anticipated to boost operational efficiencies for the CDMO.

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

How current frameworks influence coverage decisions and pricing negotiations.

Document reveals that 20 of 28 of participating Big Pharma manufacturers saw their DIO increase by an average of 5%, suggesting that large amounts of inventory do not necessarily offer protection from running low on medication.

Financial commitment will allow the firm to further build upon its resources and capabilities in assisting pharma clients.

Acquisition is expected to drive organization’s ‘next phase of growth.’

A ‘next generation’ CRM platform will gradually leave the Salesforce.com platform behind.

The deal—potentially totaling upwards of $100 million—strengthens the company’s selection of US generic prescription products.

Jasmin Patel of a-Connect provides insight on how to navigate the ebbs and flows of employment.

Expansion expected to help tackle health issues at a faster rate, company says

Annual report finds continuing impact of COVID-19 on global markets

Partnership aims to lower prescription drug costs and increase price transparency

Dr. Liz Kwo of Everly Health outlines 2023 predictions for AI, including how it can be beneficial to patients

Provider’s regulatory affairs, pharmacovigilance services expected to help increase ABC’s portfolio

A Q&A with AstraZeneca’s Country President for Belgium & Luxembourg, Keira Driansky

Dr. Troy Sarich of Janssen reveals the company's approach to tackling financial challenges as they pertain to tech

Purchase strengthens Amgen’s therapeutics portfolio

Drug safety analysis to be conducted at Rockland, MD facility

A Harvard Business School Healthcare Alumni Association C-suite Q&A with Mark Cuban, Cost Plus Drugs co-founder

With purchase, UPS Healthcare can grow coverage in Europe, LATAM

Agreement revolves around sustainability, but also features implementation of new bioprocess development methods

Purchase will help CDMO expand into European market

Kaysersberg facility’s Lab+ deal expected to bolster CDMO’s filling services

Non-exclusive deal intends to popularize RTU containment solutions within pharma industry

Deal is valued at $21.9 million

Invests $5 million to upgrade manufacturing processes

Healthcare marketing agency acquisition augments company’s commercialization portfolio

Agreement featuring UK pharma services consultancy intends to grow PharmaLex's pan-European market access presence

HCP-driven partnership calls for greater engagement across the life science sector